Compare Best Buy Co Inc (BBY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs Gilead Sciences, Inc. — how do they compare? Best Buy Co Inc trades at $83.5 (market cap $17.55B), while Gilead Sciences, Inc. trades at $135.19 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 9.6× Best Buy Co Inc's market cap, and Best Buy Co Inc pays the higher dividend (4.61%). Which is the better fit depends on your goals.
| BBY | GILD | |
|---|---|---|
Market Cap | $17.55B | $168.35B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.17 | $155.80 |
52-Week Low | $55.52 | $110.56 |
Enterprise Value | $19.93B | $191.42B |
Dividend Yield | 4.61% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
